Cellceutix Corp (CTIX) 1.4000 $CTIX
Cellceutix Stockholders Tour Company Facilities at First Annual Stockholder Meeting; Investors Express Support for Company and Disgust for Seeking Alpha Article
Marketwired - Thu Dec 17, 10:16AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today provides shareholders a re-cap of the Company's first Annual Meeting of Stockholders, held Tuesday, December 15, 2015 at the office building of Cellceutix's corporate headquarters in Beverly, Massachusetts. Cellceutix would like to thank all of the shareholders that attended.
Metastatic Ovarian Cancer Pipeline Review, H2 2015 - 9 Companies & 13 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/tp9jps/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellceutix Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Immune Design Corp. - Millennium Pharmaceuticals, Inc. - Natco Pharma Limited - Northwest Biotherapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - VG Life Sciences, Inc. Drug Profiles - DCVax-Direct - DCVax-L - Drugs for Metastatic Ovarian Cancer - E-7449 - emactuzumab - G-305 - hydroxychloroquine sorafenib tosylate - KM-3174 - LV-305 - NRCAN-019 - orteronel - SM-276001 - Vaccine for Oncology For more information visit http://www.researchandmarkets.com/research/tp9jps/metastatic
IMDZ: 21.57 (+0.79), NWBO: 4.39 (+0.18)
Cervical Cancer Pipeline Review, H2 2015 - Featuring 50+ Companies
M2 - Mon Dec 14, 9:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/vj928n/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Admedus Ltd - Advaxis, Inc. - AnGes MG, Inc. - Antigen Express, Inc. - Arbor Vita Corporation - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics, Inc. - BIND Therapeutics, Inc. - Cancer Research Technology Limited - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Genmab A/S - Genor BioPharma Co., Ltd. - Genticel S.A. - GlaxoSmithKline Plc - Hetero Drugs Limited - Kite Pharma, Inc. - LondonPharma Ltd - Mabion SA - MedImmune, LLC - MEI Pharma, Inc. - Mycenax Biotech Inc. - Nanotherapeutics, Inc. - Nektar Therapeutics - Novartis AG - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Shantha Biotechnics Limited - Sirnaomics, Inc. - Sun Pharma Advanced Research Company Ltd. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/vj...cal_cancer
ADXS: 11.92 (-0.40), ARQL: 2.05 (-0.09), BIND: 2.59 (+0.02), GSK: 39.43 (-0.40), NKTR: 15.87 (-0.04), MEIP: 1.73 (+0.08), KITE: 63.03 (-0.84), AZN: 32.80 (-0.56), AVEO: 1.03 (-0.06), NVS: 84.77 (-0.53)
Cellceutix First Annual Shareholder Meeting December 15, 2015
Marketwired - Mon Dec 14, 6:30AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reminds shareholders that tomorrow is the first annual Cellceutix shareholder meeting. The meeting will be held at 100 Cummings Center, Suite 221-E, 2nd Floor, Beverly, Massachusetts and will convene at 10:00 a.m. local time. To those attending the shareholder meeting, note that Suite 221-E, 2nd Floor is not attached to our offices, but is on the floor above our offices.
Cellceutix Completes Lab Testing of Brilacidin for Planned Phase 3 Trial for Acute Bacterial Skin and Skin Structure Infections
Marketwired - Fri Dec 11, 8:18AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders that laboratory testing of Brilacidin has been completed for use in the planned Phase 3 study in Acute Bacterial Skin and Skin Structure Infections (ABSSSI). This lot of Brilacidin API (active pharmaceutical ingredient) has now passed rigorous quality control tests. In addition, development work on lyophilizing Brilacidin has been successfully completed. The engineering run has been completed and the production run is scheduled for this month. This will allow Brilacidin for ABSSSI to be stored at room temperature or under refrigeration, a significant advantage over freezing, as was required in the past.
Candidiasis Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 07, 9:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/h6r9rb/candidiasis) has announced the addition of the "Candidiasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aureogen Biosciences, Inc. - Bakker Medical Srl - Biomar Microbial Technologies - Cellceutix Corporation - Cidara Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - General Biologicals Corporation - GlaxoSmithKline Plc - Grupo Ferrer Internacional, S.A. - Hsiri Therapeutics, LLC - iCo Therapeutics Inc. - Nanomerics Ltd - Novabiotics Limited - NovaDigm Therapeutics, Inc. - Onxeo SA - Panacela Labs, Inc. - Scynexis, Inc. - Sealife PHARMA GMBH - Sequella, Inc. - Viamet Pharmaceuticals, Inc. - Wellstat Vaccines, LLC For more information visit http://www.researchandmarkets.com/research/h6...andidiasis
CDTX: 16.64 (-0.02), GSK: 39.43 (-0.40)
Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpnfv4/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Amgen Inc. - Angiogene Pharmaceuticals Limited - Argos Therapeutics, Inc. - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bionomics Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Cerulean Pharma, Inc. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - GlaxoSmithKline Plc - Hospira, Inc. - Immune Design Corp. - Immunicum AB - Inbiopro Solutions Pvt. Ltd. - Mabion SA - Merck & Co., Inc. - NewLink Genetics Corporation - Novartis AG - Oncobiologics, Inc. - Ono Pharmaceutical Co., Ltd. - Panacea Biotec Limited - Peloton Therapeutics, Inc. - Prima BioMed Ltd. - Rexahn Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Syndax Pharmaceuticals, Inc. - TVAX Biomedical, Inc. For more information visit http://www.researchandmarkets.com/research/zp...atic_renal
IMDZ: 21.57 (+0.79), RNN: 0.37 (-0.04), CERU: 3.78 (+0.09), CLDX: 15.52 (+0.51), AMGN: 158.80 (-2.63), LLY: 84.77 (-1.45), GSK: 39.43 (-0.40), ARGS: 1.85 (unch), SNDX: (), SGEN: 41.67 (+0.24), MRK: 51.64 (-1.02), NLNK: 35.33 (-0.09), NVS: 84.77 (-0.53), XLRN: 44.50 (+0.59)
Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
Marketwired - Tue Dec 01, 9:32AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that on November 30, 2015 the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Kevetrin for the treatment of retinoblastoma, a rare form of eye cancer that begins in the retina, the light sensitive nerve tissue that lines the back of the eye. Retinoblastoma is most generally found in children, usually before the age of three, and rarely found in adults. It is sight threatening and potentially fatal if not diagnosed early.
Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant
Marketwired - Mon Nov 30, 6:30AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, announced today that Ronald Trust, PhD, MBA, has been retained as a consultant to the Company to oversee regulatory affairs pertaining to the planned Brilacidin Phase 3 program for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), among other responsibilities.
AGN: 306.58 (-2.93), ENZN: 0.76 (+0.01)
FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis
Marketwired - Wed Nov 25, 7:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Brilacidin-OM, an oral rinse formulation of the Company's novel defensin-mimetic Brilacidin, for the prevention of oral mucositis. Oral mucositis, a common and often debilitating inflammation and ulceration that occurs in the mouth as a side-effect of certain cancer treatments, afflicts approximately 450,000 patients each year in the United States and can affect the course and outcome of cancer therapy. There are no FDA approved drugs for the prevention of oral mucositis.
Beyond the Chart, What Price Data Reveals - Research on Alcobra, Control4, Contango Oil & Gas, and Cellceutix
ACCESSWIRE - Mon Nov 23, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Alcobra Ltd (NASDAQ: ADHD), Control4 Corp (NASDAQ: CTRL), Contango Oil & Gas Co (NYSE: MCF) and Cellceutix Corp (OTC: CTIX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
MCF: 6.08 (-0.15), ADHD: 5.81 (-0.03), CTRL: 6.91 (-0.01)
Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
Marketwired - Mon Nov 23, 6:30AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration, or FDA, has granted Orphan Drug Designation to Kevetrin for the treatment of retinoblastoma, a rare form of eye cancer that begins in the retina, the light sensitive nerve tissue that lines the back of the eye. Retinoblastoma is most generally found in children, usually before the age of three, and rarely found in adults. It is sight threatening and potentially fatal if not diagnosed early.
Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer
Marketwired - Mon Nov 16, 6:31AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reports that, based upon ongoing laboratory studies, the Company intends to use docetaxel for the combination therapy arm in the planned Phase 2 clinical trial to treat patients with platinum-resistance ovarian cancer. Cellceutix is designing the multi-arm study to evaluate Kevetrin as a monotherapy and as a component of combination therapy.
Penny Stocks Alerts for Creative Edge Nutrition, EKSO BIONICS, Cellceutix, Angie's List, MannKind, and Sirius XM
PR Newswire - Fri Nov 13, 8:30AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Creative Edge Nutrition (OTCMKTS:FITX), EKSO BIONICS (OTCBB:EKSO), Cellceutix (OTCMKTS:CTIX), Angie's List (NASDAQ:ANGI), MannKind (NASDAQ:MNKD), and Sirius XM (NASDAQ:SIRI).
ANGI: 8.99 (-0.23), MNKD: 1.48 (-0.07), SIRI: 3.99 (-0.03)
Cellceutix Completes Cohort in Kevetrin Clinical Trial; Cheers to Ocata Therapeutics
Marketwired - Wed Nov 11, 9:34AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to report that on Monday, November 9, 2015, the sixth qualifying patient in the present cohort received their third treatment of Kevetrin, our lead anti-cancer drug in a Phase 1 clinical trial for the treatment of advanced solid tumors, at 750 mg/m2. To wit, enrollment in the Kevetrin Phase 1 clinical trial is now closed to new subjects. The decision to formally conclude the trial will now be reviewed by the Company and Principal Investigator.
OCAT: 8.49 (unch)
Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015
Marketwired - Tue Nov 10, 9:51AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2015 with the Securities and Exchange Commission. A copy of the report is available to be viewed or downloaded on the Company's website.
Anthrax - Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bjw94/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Altimmune, Inc. - Aphios Corporation - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - Cellceutix Corporation - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Oragenics, Inc. - PaxVax - Pfenex Inc. - PharmAthene, Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics Limited - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - United Therapeutics Corporation - VLP Biotech, Inc. For more information visit http://www.researchandmarkets.com/research/3bjw94/anthrax
DVAX: 27.08 (-0.19), TTPH: 9.98 (+0.33), ADRO: 29.56 (-2.18), EBS: 38.30 (+0.77), UTHR: 155.18 (-2.96), BMY: 67.64 (-1.64), PFNX: 11.87 (-0.10), PIP: 1.53 (-0.08), IBIO: 0.60 (+0.03), OGEN: 1.52 (+0.30)
Technical Review On Stocks From Varied Sectors - Research on Cellceutix, Agrieuro, Cannabis Science and Hyperdynamics
ACCESSWIRE - Mon Nov 02, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / November 2, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cellceutix Corp. (OTC: CTIX), Agrieuro Corp. (OTC: EURI), Cannabis Science Inc. (OTC: CBIS) and Hyperdynamics Corporation (OTC: HDYN). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.
How it All Plays Out - Research on Arena Pharmaceuticals, XOMA, Ekso Bionics and Cellceutix
ACCESSWIRE - Fri Oct 30, 7:17AM CDT
NEW YORK, NY / ACCESSWIRE / October 30, 2015 / Moments ago, Trader's Choice released another issue of its world-class newsletter in which it took the time to review and explain some of the most talked about situations on wall street today: Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Ekso Bionics Holdings, Inc. (OTC: EKSO) and Cellceutix Corp (OTC: CTIX).
ARNA: 1.90 (+0.07), XOMA: 1.36 (-0.02)
Cellceutix Provides Brilacidin Update; New Class of Antibiotics to Enter Phase 3
Marketwired - Fri Oct 30, 6:30AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to provide an update on brilacidin, a new class of immunomodulatory antibiotics known as Host Defense Protein (HDP) mimics or defensin-mimetics. Last year, the Company successfully completed a phase 2b study in patients with Acute Bacterial Skin and Skin Structure Infections (ABBBSI). There were there were no serious adverse events (SAEs) that were deemed by the principal investigator (PI) as related to study drug. Efficacy was high across all brilacidin treatment groups, including the two single-dose groups, and similar to daptomycin, the active comparator. "To show similarity to a gold standard such as daptomycin is impressive -- especially when our drug is given one time, while daptomycin is given every day for seven days," said Leo Ehrlich, Chief Executive Officer at Cellceutix. "I am very happy that we acquired brilacidin and the other HDP mimics. We acquired the HDP mimics for a song, a move that, considering all that we've already accomplished, I anticipate to turn out as a phenomenal business decision for Cellceutix shareholders."
Cellceutix Stockholders Tour Company Facilities at First Annual Stockholder Meeting; Investors Express Support for Company and Disgust for Seeking Alpha Article
Marketwired - Thu Dec 17, 10:16AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today provides shareholders a re-cap of the Company's first Annual Meeting of Stockholders, held Tuesday, December 15, 2015 at the office building of Cellceutix's corporate headquarters in Beverly, Massachusetts. Cellceutix would like to thank all of the shareholders that attended. Metastatic Ovarian Cancer Pipeline Review, H2 2015 - 9 Companies & 13 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/tp9jps/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellceutix Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Immune Design Corp. - Millennium Pharmaceuticals, Inc. - Natco Pharma Limited - Northwest Biotherapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - VG Life Sciences, Inc. Drug Profiles - DCVax-Direct - DCVax-L - Drugs for Metastatic Ovarian Cancer - E-7449 - emactuzumab - G-305 - hydroxychloroquine sorafenib tosylate - KM-3174 - LV-305 - NRCAN-019 - orteronel - SM-276001 - Vaccine for Oncology For more information visit http://www.researchandmarkets.com/research/tp9jps/metastatic
IMDZ: 21.57 (+0.79), NWBO: 4.39 (+0.18)
Cervical Cancer Pipeline Review, H2 2015 - Featuring 50+ Companies
M2 - Mon Dec 14, 9:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/vj928n/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Admedus Ltd - Advaxis, Inc. - AnGes MG, Inc. - Antigen Express, Inc. - Arbor Vita Corporation - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics, Inc. - BIND Therapeutics, Inc. - Cancer Research Technology Limited - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Genmab A/S - Genor BioPharma Co., Ltd. - Genticel S.A. - GlaxoSmithKline Plc - Hetero Drugs Limited - Kite Pharma, Inc. - LondonPharma Ltd - Mabion SA - MedImmune, LLC - MEI Pharma, Inc. - Mycenax Biotech Inc. - Nanotherapeutics, Inc. - Nektar Therapeutics - Novartis AG - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Shantha Biotechnics Limited - Sirnaomics, Inc. - Sun Pharma Advanced Research Company Ltd. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/vj...cal_cancer
ADXS: 11.92 (-0.40), ARQL: 2.05 (-0.09), BIND: 2.59 (+0.02), GSK: 39.43 (-0.40), NKTR: 15.87 (-0.04), MEIP: 1.73 (+0.08), KITE: 63.03 (-0.84), AZN: 32.80 (-0.56), AVEO: 1.03 (-0.06), NVS: 84.77 (-0.53)
Cellceutix First Annual Shareholder Meeting December 15, 2015
Marketwired - Mon Dec 14, 6:30AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reminds shareholders that tomorrow is the first annual Cellceutix shareholder meeting. The meeting will be held at 100 Cummings Center, Suite 221-E, 2nd Floor, Beverly, Massachusetts and will convene at 10:00 a.m. local time. To those attending the shareholder meeting, note that Suite 221-E, 2nd Floor is not attached to our offices, but is on the floor above our offices. Cellceutix Completes Lab Testing of Brilacidin for Planned Phase 3 Trial for Acute Bacterial Skin and Skin Structure Infections
Marketwired - Fri Dec 11, 8:18AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders that laboratory testing of Brilacidin has been completed for use in the planned Phase 3 study in Acute Bacterial Skin and Skin Structure Infections (ABSSSI). This lot of Brilacidin API (active pharmaceutical ingredient) has now passed rigorous quality control tests. In addition, development work on lyophilizing Brilacidin has been successfully completed. The engineering run has been completed and the production run is scheduled for this month. This will allow Brilacidin for ABSSSI to be stored at room temperature or under refrigeration, a significant advantage over freezing, as was required in the past. Candidiasis Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 07, 9:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/h6r9rb/candidiasis) has announced the addition of the "Candidiasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aureogen Biosciences, Inc. - Bakker Medical Srl - Biomar Microbial Technologies - Cellceutix Corporation - Cidara Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - General Biologicals Corporation - GlaxoSmithKline Plc - Grupo Ferrer Internacional, S.A. - Hsiri Therapeutics, LLC - iCo Therapeutics Inc. - Nanomerics Ltd - Novabiotics Limited - NovaDigm Therapeutics, Inc. - Onxeo SA - Panacela Labs, Inc. - Scynexis, Inc. - Sealife PHARMA GMBH - Sequella, Inc. - Viamet Pharmaceuticals, Inc. - Wellstat Vaccines, LLC For more information visit http://www.researchandmarkets.com/research/h6...andidiasis
CDTX: 16.64 (-0.02), GSK: 39.43 (-0.40)
Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpnfv4/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Amgen Inc. - Angiogene Pharmaceuticals Limited - Argos Therapeutics, Inc. - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bionomics Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Cerulean Pharma, Inc. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - GlaxoSmithKline Plc - Hospira, Inc. - Immune Design Corp. - Immunicum AB - Inbiopro Solutions Pvt. Ltd. - Mabion SA - Merck & Co., Inc. - NewLink Genetics Corporation - Novartis AG - Oncobiologics, Inc. - Ono Pharmaceutical Co., Ltd. - Panacea Biotec Limited - Peloton Therapeutics, Inc. - Prima BioMed Ltd. - Rexahn Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Syndax Pharmaceuticals, Inc. - TVAX Biomedical, Inc. For more information visit http://www.researchandmarkets.com/research/zp...atic_renal
IMDZ: 21.57 (+0.79), RNN: 0.37 (-0.04), CERU: 3.78 (+0.09), CLDX: 15.52 (+0.51), AMGN: 158.80 (-2.63), LLY: 84.77 (-1.45), GSK: 39.43 (-0.40), ARGS: 1.85 (unch), SNDX: (), SGEN: 41.67 (+0.24), MRK: 51.64 (-1.02), NLNK: 35.33 (-0.09), NVS: 84.77 (-0.53), XLRN: 44.50 (+0.59)
Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
Marketwired - Tue Dec 01, 9:32AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that on November 30, 2015 the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Kevetrin for the treatment of retinoblastoma, a rare form of eye cancer that begins in the retina, the light sensitive nerve tissue that lines the back of the eye. Retinoblastoma is most generally found in children, usually before the age of three, and rarely found in adults. It is sight threatening and potentially fatal if not diagnosed early. Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant
Marketwired - Mon Nov 30, 6:30AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, announced today that Ronald Trust, PhD, MBA, has been retained as a consultant to the Company to oversee regulatory affairs pertaining to the planned Brilacidin Phase 3 program for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), among other responsibilities. AGN: 306.58 (-2.93), ENZN: 0.76 (+0.01)
FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis
Marketwired - Wed Nov 25, 7:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Brilacidin-OM, an oral rinse formulation of the Company's novel defensin-mimetic Brilacidin, for the prevention of oral mucositis. Oral mucositis, a common and often debilitating inflammation and ulceration that occurs in the mouth as a side-effect of certain cancer treatments, afflicts approximately 450,000 patients each year in the United States and can affect the course and outcome of cancer therapy. There are no FDA approved drugs for the prevention of oral mucositis. Beyond the Chart, What Price Data Reveals - Research on Alcobra, Control4, Contango Oil & Gas, and Cellceutix
ACCESSWIRE - Mon Nov 23, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Alcobra Ltd (NASDAQ: ADHD), Control4 Corp (NASDAQ: CTRL), Contango Oil & Gas Co (NYSE: MCF) and Cellceutix Corp (OTC: CTIX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
MCF: 6.08 (-0.15), ADHD: 5.81 (-0.03), CTRL: 6.91 (-0.01)
Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
Marketwired - Mon Nov 23, 6:30AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration, or FDA, has granted Orphan Drug Designation to Kevetrin for the treatment of retinoblastoma, a rare form of eye cancer that begins in the retina, the light sensitive nerve tissue that lines the back of the eye. Retinoblastoma is most generally found in children, usually before the age of three, and rarely found in adults. It is sight threatening and potentially fatal if not diagnosed early. Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer
Marketwired - Mon Nov 16, 6:31AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reports that, based upon ongoing laboratory studies, the Company intends to use docetaxel for the combination therapy arm in the planned Phase 2 clinical trial to treat patients with platinum-resistance ovarian cancer. Cellceutix is designing the multi-arm study to evaluate Kevetrin as a monotherapy and as a component of combination therapy. Penny Stocks Alerts for Creative Edge Nutrition, EKSO BIONICS, Cellceutix, Angie's List, MannKind, and Sirius XM
PR Newswire - Fri Nov 13, 8:30AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Creative Edge Nutrition (OTCMKTS:FITX), EKSO BIONICS (OTCBB:EKSO), Cellceutix (OTCMKTS:CTIX), Angie's List (NASDAQ:ANGI), MannKind (NASDAQ:MNKD), and Sirius XM (NASDAQ:SIRI).
ANGI: 8.99 (-0.23), MNKD: 1.48 (-0.07), SIRI: 3.99 (-0.03)
Cellceutix Completes Cohort in Kevetrin Clinical Trial; Cheers to Ocata Therapeutics
Marketwired - Wed Nov 11, 9:34AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to report that on Monday, November 9, 2015, the sixth qualifying patient in the present cohort received their third treatment of Kevetrin, our lead anti-cancer drug in a Phase 1 clinical trial for the treatment of advanced solid tumors, at 750 mg/m2. To wit, enrollment in the Kevetrin Phase 1 clinical trial is now closed to new subjects. The decision to formally conclude the trial will now be reviewed by the Company and Principal Investigator. OCAT: 8.49 (unch)
Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015
Marketwired - Tue Nov 10, 9:51AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2015 with the Securities and Exchange Commission. A copy of the report is available to be viewed or downloaded on the Company's website. Anthrax - Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bjw94/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Altimmune, Inc. - Aphios Corporation - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - Cellceutix Corporation - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Oragenics, Inc. - PaxVax - Pfenex Inc. - PharmAthene, Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics Limited - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - United Therapeutics Corporation - VLP Biotech, Inc. For more information visit http://www.researchandmarkets.com/research/3bjw94/anthrax
DVAX: 27.08 (-0.19), TTPH: 9.98 (+0.33), ADRO: 29.56 (-2.18), EBS: 38.30 (+0.77), UTHR: 155.18 (-2.96), BMY: 67.64 (-1.64), PFNX: 11.87 (-0.10), PIP: 1.53 (-0.08), IBIO: 0.60 (+0.03), OGEN: 1.52 (+0.30)
Technical Review On Stocks From Varied Sectors - Research on Cellceutix, Agrieuro, Cannabis Science and Hyperdynamics
ACCESSWIRE - Mon Nov 02, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / November 2, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cellceutix Corp. (OTC: CTIX), Agrieuro Corp. (OTC: EURI), Cannabis Science Inc. (OTC: CBIS) and Hyperdynamics Corporation (OTC: HDYN). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.
How it All Plays Out - Research on Arena Pharmaceuticals, XOMA, Ekso Bionics and Cellceutix
ACCESSWIRE - Fri Oct 30, 7:17AM CDT
NEW YORK, NY / ACCESSWIRE / October 30, 2015 / Moments ago, Trader's Choice released another issue of its world-class newsletter in which it took the time to review and explain some of the most talked about situations on wall street today: Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Ekso Bionics Holdings, Inc. (OTC: EKSO) and Cellceutix Corp (OTC: CTIX).
ARNA: 1.90 (+0.07), XOMA: 1.36 (-0.02)
Cellceutix Provides Brilacidin Update; New Class of Antibiotics to Enter Phase 3
Marketwired - Fri Oct 30, 6:30AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to provide an update on brilacidin, a new class of immunomodulatory antibiotics known as Host Defense Protein (HDP) mimics or defensin-mimetics. Last year, the Company successfully completed a phase 2b study in patients with Acute Bacterial Skin and Skin Structure Infections (ABBBSI). There were there were no serious adverse events (SAEs) that were deemed by the principal investigator (PI) as related to study drug. Efficacy was high across all brilacidin treatment groups, including the two single-dose groups, and similar to daptomycin, the active comparator. "To show similarity to a gold standard such as daptomycin is impressive -- especially when our drug is given one time, while daptomycin is given every day for seven days," said Leo Ehrlich, Chief Executive Officer at Cellceutix. "I am very happy that we acquired brilacidin and the other HDP mimics. We acquired the HDP mimics for a song, a move that, considering all that we've already accomplished, I anticipate to turn out as a phenomenal business decision for Cellceutix shareholders." 
